Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $9.40 Consensus PT from Analysts

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has earned a consensus rating of “Hold” from the six brokerages that are presently covering the stock, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $9.40.

RXRX has been the topic of several research reports. KeyCorp decreased their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Jefferies Financial Group decreased their price objective on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Leerink Partners dropped their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC decreased their target price on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday, September 4th.

Recursion Pharmaceuticals Stock Performance

RXRX opened at $6.11 on Friday. The stock has a market cap of $1.45 billion, a P/E ratio of -3.82 and a beta of 0.80. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. The firm has a fifty day moving average price of $6.88 and a 200 day moving average price of $8.09. Recursion Pharmaceuticals has a 1 year low of $4.97 and a 1 year high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The firm had revenue of $14.42 million for the quarter, compared to analysts’ expectations of $11.96 million. During the same period in the previous year, the company earned ($0.38) earnings per share. The company’s revenue was up 30.9% compared to the same quarter last year. Equities research analysts anticipate that Recursion Pharmaceuticals will post -1.58 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Christopher Gibson sold 20,000 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $6.16, for a total value of $123,200.00. Following the sale, the chief executive officer now directly owns 762,656 shares in the company, valued at approximately $4,697,960.96. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Christopher Gibson sold 20,000 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total value of $123,200.00. Following the transaction, the chief executive officer now owns 762,656 shares of the company’s stock, valued at $4,697,960.96. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Michael Secora sold 15,000 shares of the company’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $6.17, for a total value of $92,550.00. Following the transaction, the chief financial officer now directly owns 1,377,756 shares of the company’s stock, valued at approximately $8,500,754.52. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 263,129 shares of company stock worth $1,826,444 in the last 90 days. Corporate insiders own 15.75% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Benjamin F. Edwards & Company Inc. acquired a new stake in Recursion Pharmaceuticals during the 1st quarter worth $26,000. GAMMA Investing LLC grew its holdings in shares of Recursion Pharmaceuticals by 1,588.4% during the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after purchasing an additional 6,036 shares during the last quarter. Amalgamated Bank increased its position in shares of Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after purchasing an additional 2,459 shares in the last quarter. Midwest Financial Group LLC purchased a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter valued at about $90,000. Finally, Xponance Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter valued at about $98,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.